Denali Therapeutics (DNLI) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 199.5% versus a gain of 28.6%. Over five years, TNGX leads with a +55.6% price change compared with -57.9% for DNLI. Tango Therapeutics is the larger company by market cap ($3.57 billion vs $2.95 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | TNGX |
|---|---|---|
| Share price | $18.45 | $21.17 |
| Market cap | $2.95B | $3.57B |
| 1-day change | -3.71% | -3.05% |
| YTD return | +16.05% | +146.39% |
| 1-year return | +28.59% | +199.45% |
| 5-year return | -57.95% | +55.60% |
| EPS (TTM) | $-2.84 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $62.38M |
| Revenue growth (YoY) | — | +48.29% |
| Net income (latest FY) | $-512.54M | $-101.59M |
| Operating margin | — | -178.39% |
| Net margin | — | -162.85% |
| 52-week high | $27.30 | $34.39 |
| 52-week low | $13.75 | $6.69 |
| Distance from 52-week high | -32.42% | -38.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +95.45% | +113.47% |
| Average volume | 1.61M | 2.61M |
| Shares outstanding | 159.85M | 168.61M |
| Employees | 503 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed DNLI by 170.9 percentage points over the past year.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
DNLI vs TNGX FAQ
Which is bigger, Denali Therapeutics or Tango Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.57B compared with $2.95B for Denali Therapeutics (DNLI).
Which stock has performed better over the past year, DNLI or TNGX?
TNGX returned +199.45% over the past 12 months, compared with +28.59% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Tango Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Denali Therapeutics and Biotechnology: Pharmaceutical Preparations for Tango Therapeutics.